Quantitative determination of the epidermal growth factor receptor in cervical cancer and normal cervical epithelium by 2-color flow cytometry: Evidence for down-regulation in cervical cancer
Open Access
- 22 August 1997
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 74 (4), 365-373
- https://doi.org/10.1002/(sici)1097-0215(19970822)74:4<365::aid-ijc1>3.0.co;2-t
Abstract
Expression of epidermal growth factor receptor (EGFR) was quantified by 2‐color flow cytometry in cervical cancer (n = 73) and normal cervical epithelium (n = 11). EGFR was determined using a murine monoclonal EGFR antibody, and number of bound antibodies was quantified adding calibration beads with defined antigenic binding sites. Tumor cells were identified by simultaneous DNA staining. Epithelium of normal cervical tissue was detected by labeling for cytokeratin. Results were compared with EGFR quantification by autoradiography on cryostat sections using a radioligand binding assay. A high degree of correlation was found between the 2 methods. In cervical carcinomas 14,600 binding sites/cell (median; range, 160–283,000 binding sites/cell) were detected, considerably less compared with normal cervical squamous epithelium, which was 30,700 binding sites/cell (median; range, 19,900–44,000 binding sites/cell). This finding clearly contrasts with other reports of enhanced EGFR expression in cervical cancer. The discrepancy may be explained by contamination of tissue homogenates used for radioligand or enzyme immunosorbent assays by non‐epithelial tissue elements with low or absent EGFR expression. Interference with quantitative EGFR determination in epithelial cells may result in false low estimates of EGFR expression predominantly in normal cervical tissue. This should be avoided by identifying tumor and normal epithelial cells prior to analysis. In our study, 63% of cervical cancers expressed low levels of EGFR compared with normal cervical epithelium, and only 10% showed overexpression. There is evidence that cervical carcinomas overexpressing EGFR represent a small, but biologically distinct group of cervical cancers exhibiting enhanced aggressiveness associated with poor survival of the patients. Int. J. Cancer 74:365–373, 1997.This publication has 20 references indexed in Scilit:
- Expression of Epidermal Growth Factor Receptor in Carcinoma of the CervixGynecologic Oncology, 1996
- DNA cell-cycle analysis of cervical cancer by flow cytometry using simultaneous cytokeratin labelling for identification of tumour cellsZeitschrift für Krebsforschung und Klinische Onkologie, 1995
- Flow cytometric detection and quantitation of the epidermal growth factor receptor in comparison to Scatchard analysis in human bladder carcinoma cell linesCytometry, 1994
- Flow cytometric method for the measurement of epidermal growth factor receptor and comparison with the radio‐ligand binding assayCytometry, 1994
- Multiparameter flow-cytometric quantitation of epidermal growth factor receptor and c-erbB-2 oncoprotein in normal and neoplastic tissues of the female genital tractGynecologic Oncology, 1991
- Immunohistochemical detection of the epidermal growth factor receptor in paraffin‐embedded human tissuesThe Journal of Pathology, 1991
- Expression of ras oncogene product and EGF receptor in cervical squamous cell carcinomas and its relationship to lymph node involvementGynecologic Oncology, 1991
- Structure and Function of Human Amphiregulin: A Member of the Epidermal Growth Factor FamilyScience, 1989
- Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequencesNature, 1984
- A rapid technique for isolation of viable tumor cells from solid tumors: Use of the tumor cells for induction and measurement of cell-mediated cytotoxic responsesEuropean Journal of Cancer and Clinical Oncology, 1982